NASDAQ:TPTXTurning Point Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Turning Point Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $56.99 -1.71 (-2.91 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$56.51Now: $56.99▼$60.6550-Day Range$57.86MA: $62.74▼$68.0752-Week Range$31.30Now: $56.99▼$72.03Volume299,737 shsAverage Volume253,202 shsMarket Capitalization$2.05 billionP/E RatioN/ADividend YieldN/ABeta1.21 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Turning Point Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib (TPX-0005) is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and a series of ALK inhibitors. The company was incorporated in 2013 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 4.5 Analyst's Opinion Consensus RatingTurning Point Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $73.57, Turning Point Therapeutics has a potential upside of 29.1% from its current price of $56.99.Amount of Analyst CoverageTurning Point Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.9 Community Rank Outperform VotesTurning Point Therapeutics has received 51 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTurning Point Therapeutics has received 38 “underperform” votes. (Add your “underperform” vote.)Community SentimentTurning Point Therapeutics has received 57.30% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Turning Point Therapeutics and other stocks. Vote “Outperform” if you believe TPTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TPTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTurning Point Therapeutics does not currently pay a dividend.Dividend GrowthTurning Point Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Turning Point Therapeutics insiders have sold 1,177.92% more of their company's stock than they have bought. Specifically, they have bought $249,960.00 in company stock and sold $3,194,285.00 in company stock.Percentage Held by InsidersOnly 23.20% of the stock of Turning Point Therapeutics is held by insiders.Percentage Held by Institutions81.58% of the stock of Turning Point Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Turning Point Therapeutics are expected to decrease in the coming year, from ($4.47) to ($5.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Turning Point Therapeutics is -15.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Turning Point Therapeutics is -15.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTurning Point Therapeutics has a P/B Ratio of 5.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.68 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TPTX Previous Symbol CUSIPN/A CIKN/A Webwww.tptherapeutics.com Phone858-926-5251Debt Debt-to-Equity Ratio0.01 Current Ratio34.91 Quick Ratio34.91Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.28 per share Price / Book5.05Profitability EPS (Most Recent Fiscal Year)($2.99) Net Income$-72,130,000.00 Net MarginsN/A Return on Equity-32.81% Return on Assets-31.55%Miscellaneous Employees50 Outstanding Shares35,920,000Market Cap$2.05 billion Next Earnings Date8/11/2020 (Estimated) OptionableNot Optionable $56.99 -1.71 (-2.91 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive TPTX News and Ratings via Email Sign-up to receive the latest news and ratings for TPTX and its competitors with MarketBeat's FREE daily newsletter. Turning Point Therapeutics (NASDAQ:TPTX) Frequently Asked Questions How has Turning Point Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Turning Point Therapeutics' stock was trading at $40.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TPTX shares have increased by 40.6% and is now trading at $56.99. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Turning Point Therapeutics? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Turning Point Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Turning Point Therapeutics. When is Turning Point Therapeutics' next earnings date? Turning Point Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Turning Point Therapeutics. How were Turning Point Therapeutics' earnings last quarter? Turning Point Therapeutics (NASDAQ:TPTX) issued its quarterly earnings results on Tuesday, May, 12th. The company reported ($1.69) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.66) by $1.03. View Turning Point Therapeutics' earnings history. What price target have analysts set for TPTX? 7 brokers have issued twelve-month target prices for Turning Point Therapeutics' stock. Their forecasts range from $56.00 to $90.00. On average, they anticipate Turning Point Therapeutics' share price to reach $73.57 in the next twelve months. This suggests a possible upside of 29.1% from the stock's current price. View analysts' price targets for Turning Point Therapeutics. Has Turning Point Therapeutics been receiving favorable news coverage? Media stories about TPTX stock have been trending very positive on Saturday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Turning Point Therapeutics earned a coverage optimism score of 4.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Turning Point Therapeutics. Are investors shorting Turning Point Therapeutics? Turning Point Therapeutics saw a increase in short interest during the month of July. As of July 31st, there was short interest totaling 3,120,000 shares, an increase of 9.1% from the July 15th total of 2,860,000 shares. Based on an average daily volume of 381,500 shares, the days-to-cover ratio is presently 8.2 days. Approximately 10.2% of the shares of the stock are sold short. View Turning Point Therapeutics' Short Interest. Who are some of Turning Point Therapeutics' key competitors? Some companies that are related to Turning Point Therapeutics include Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), ACADIA Pharmaceuticals (ACAD), Emergent Biosolutions (EBS), Mirati Therapeutics (MRTX), Myokardia (MYOK), Ultragenyx Pharmaceutical (RARE), Reata Pharmaceuticals (RETA), United Therapeutics (UTHR), Zai Lab (ZLAB), Schrodinger (SDGR) and Legend Biotech (LEGN). View all competitors. What other stocks do shareholders of Turning Point Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Turning Point Therapeutics investors own include AbbVie (ABBV), Pfizer (PFE), Enterprise Products Partners (EPD), GlaxoSmithKline (GSK), GW Pharmaceuticals PLC- (GWPH), ACADIA Pharmaceuticals (ACAD), Energy Transfer LP Unit (ET), General Mills (GIS), Intel (INTC) and Johnson & Johnson (JNJ). Who are Turning Point Therapeutics' key executives? Turning Point Therapeutics' management team includes the following people: Dr. Athena Maria Countouriotis, Pres, CEO & Director (Age 47)Dr. Jingrong Jean Cui Ph.D., Scientific Founder, Chief Scientific Officer & Director (Age 55)Mr. Brian L. Baker MS, CPA, VP of Fin. & Admin. (Age 52)Mr. James S. Mazzola, Sr. VP of Corp. Communication & Investor RelationsMs. Annette C. North, Exec. VP, Gen. Counsel & Company Sec. When did Turning Point Therapeutics IPO? (TPTX) raised $167 million in an IPO on Wednesday, April 17th 2019. The company issued 9,300,000 shares at a price of $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities served as the underwriters for the IPO and Canaccord Genuity was co-manager. What is Turning Point Therapeutics' stock symbol? Turning Point Therapeutics trades on the NASDAQ under the ticker symbol "TPTX." Who are Turning Point Therapeutics' major shareholders? Turning Point Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Jennison Associates LLC (1.77%), Candriam Luxembourg S.C.A. (0.66%), Emerald Advisers LLC (0.60%), Emerald Mutual Fund Advisers Trust (0.54%), Swiss National Bank (0.21%) and New York State Common Retirement Fund (0.09%). Company insiders that own Turning Point Therapeutics stock include Athena Countouriotis, Brian Lee Baker, Carl L Gordon, Cormorant Asset Management, Lp, Jingrong Jean Cui, Simeon George and Yi Larson. View institutional ownership trends for Turning Point Therapeutics. Which major investors are selling Turning Point Therapeutics stock? TPTX stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Strs Ohio, Chartwell Investment Partners LLC, and Virtus ETF Advisers LLC. View insider buying and selling activity for Turning Point Therapeutics. Which major investors are buying Turning Point Therapeutics stock? TPTX stock was acquired by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, Candriam Luxembourg S.C.A., Swiss National Bank, Asymmetry Capital Management L.P., Rafferty Asset Management LLC, Arizona State Retirement System, and Principal Financial Group Inc.. Company insiders that have bought Turning Point Therapeutics stock in the last two years include Athena Countouriotis, Brian Lee Baker, Carl L Gordon, Cormorant Asset Management, Lp, Simeon George, and Yi Larson. View insider buying and selling activity for Turning Point Therapeutics. How do I buy shares of Turning Point Therapeutics? Shares of TPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Turning Point Therapeutics' stock price today? One share of TPTX stock can currently be purchased for approximately $56.99. How big of a company is Turning Point Therapeutics? Turning Point Therapeutics has a market capitalization of $2.05 billion. The company earns $-72,130,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Turning Point Therapeutics employs 50 workers across the globe. What is Turning Point Therapeutics' official website? The official website for Turning Point Therapeutics is www.tptherapeutics.com. How can I contact Turning Point Therapeutics? Turning Point Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The company can be reached via phone at 858-926-5251 or via email at [email protected] This page was last updated on 8/8/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
